INFO & CONTACTS:  +39 02 2390 1

A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Duca Matteo

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: HER3-DXd

Pathologies: Advanced Solid Tumours, Melanoma, Pancreatic cancer, Lung cancer, Breast cancer, Endometrial cancer, Esophageal tumors, Cervical tumor, Prostate tumors, Head and neck cancers, Ovarian tumors, Urological cancers (kidney, bladder, urinary tract, others)

ClinicalTrials.gov: Read the details about clinical trials

Phase 2 study designed to assess the safety and efficacy of HER3-DXd monotherapy in subjects with refractory locally advanced unresectable or metastatic solid tumors that have been previously treated with ≥1 prior line of systemic anticancer therapy.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe